VECIMA-NETWORKS
9.5.2024 13:31:32 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) today announced that VECTOR TECH SOLUTIONS is deploying Vecima’s Entra® SC-1D Access Node and Entra® Access Controller (EAC) solutions for ASTA-NET, a telecommunications provider in Poland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509796116/en/
The collaboration underscores Vecima’s commitment to expanding its footprint in the European market, with VECTOR TECH SOLUTIONS providing local expertise as a Vecima reseller in Poland. The deployment for ASTA-NET gives the Polish internet and communications technology (ICT) integrator an instant customer success story as it introduces Vecima’s innovative Remote MACPHY Device (RMD) Distributed Access Architecture (DAA) node to the Poland market.
The SC-1D, a cornerstone of the Entra family, is designed to enable operators like ASTA-NET to transition toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability.
Complementing the SC-1D, Vecima’s Entra Access Controller (EAC) serves as a centralized management platform that orchestrates the complex interactions between the core network and distributed access devices. The EAC ensures seamless integration and optimal performance of the DAA ecosystem, facilitating advanced features such as dynamic bandwidth allocation and network virtualization.
ASTA-NET’s adoption of Vecima’s technology through VECTOR TECH SOLUTIONS represents a pivotal step in enhancing its network infrastructure to deliver superior broadband services. With the Entra SC 1-D and EAC, ASTA-NET can position itself at the forefront of digital transformation.
“Collaboration with global broadband technology providers such as Vecima is a great honor,” said Artur Salwach, Sales Managing Director at VECTOR TECH SOLUTIONS. “We are glad we can cooperate with the world's leaders to provide solutions to Polish telecommunications operators such as ASTA-NET and develop their business.”
"Vecima and VECTOR TECH SOLUTIONS are closely aligned in our shared objective of advancing Poland's telecommunications sector," said German Iaryczower, Senior Vice President, Global Sales & Marketing at Vecima. "Our strategic partnership will continue to elevate and expand connectivity throughout Poland.”
For more information about Vecima’s Entra DAA platform, visit vecima.com/network-access/interoperable-daa-solutions.
About ASTA-NET
ASTA-NET, a company of the ASTA Group, present on the market since 1989, a leader in providing telecommunications services in northern Greater Poland and neighboring areas of the West Pomeranian Voivodeship. ASTA-NET covers over 140,000 households and provides services to over 63,000 individual and business clients. Its success is based on bold and permanent investments in network development and product development. The treasure of ASTA-NET is its qualified staff - technology enthusiasts and people focused on customer needs. The company's goal is to be the operator of first choice, i.e. the most desirable provider of multimedia services.
About VECTOR TECH SOLUTIONS
Polish integrator that designs and implements modern ICT solutions, responding to the growing market needs. VECTOR TECH SOLUTIONS supports organizations from various industries, guaranteeing high quality services in the field of optical technologies, uninterrupted power supply, cybersecurity, IT infrastructure and IP networks. The basis for the provided services is a good understanding of clients' business and certified technological knowledge. Everything they have learned over many years while conducting large and complex projects helps adapt their solutions to various and multi-faceted business challenges. Learn more at vectortechsolutions.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509796116/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
